[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641754":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":66,"collaborators":30,"id":68,"slug":30,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":30,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":30,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":30,"overallStatus":51,"whyStopped":30,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":91,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},{"fullName":5,"class":6},"Merck Sharp & Dohme LLC","INDUSTRY",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: MK-8527","EXPERIMENTAL","Participants will receive a single dose of MK-8527 with food and a single dose of MK-8527 without food.",[13],"Drug: MK-8527",{"label":15,"type":10,"description":16,"interventionNames":17},"Part 2: MK-8527 + Probenecid","Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with probenecid.",[13,18],"Drug: Probenecid",{"label":20,"type":10,"description":21,"interventionNames":22},"Part 3: MK-8527 + Itraconazole","Participants will receive a single dose of MK-8527 alone and a single dose of MK-8527 in combination with itraconazole.",[13,23],"Drug: Itraconazole",[25,31,34],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","MK-8527","Oral tablet",[9,15,20],null,{"type":26,"name":32,"description":28,"armGroupLabels":33,"otherNames":30},"Probenecid",[15],{"type":26,"name":35,"description":36,"armGroupLabels":37,"otherNames":30},"Itraconazole","Oral solution",[20],[39],{"name":40,"affiliation":5,"role":41},"Medical Director","STUDY_DIRECTOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":30,"email":47},"Toll Free Number","CONTACT","1-888-577-8839","Trialsites@msd.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Fortrea Clinical Research Unit Inc ( Site 0001)","RECRUITING","Daytona Beach","Florida","32117","United States",{"type":57,"coordinates":58},"Point",[59,60],-81.02283,29.21081,{"lat":60,"lon":59},[63],{"name":64,"role":45,"phone":65,"phoneExt":30,"email":30},"Study Coordinator","386-366-6400",{"type":67,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100641754",false,"NCT07661108","A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)","An Open-label, Phase 1 Study to Individually Characterize the Food Effect, the Drug-Drug Interaction Effect of OAT Inhibition, and the Drug-Drug Interaction Effect of P-glycoprotein Inhibition on the Pharmacokinetics of MK-8527 in Healthy Adult Participants","Inclusion Criteria:\n\n* Be in good health\n* Has a body mass index (BMI) between 18 and 32 kg\u002Fm\\^2, inclusive\n\nExclusion Criteria:\n\n* Has an estimated glomerular filtration rate (eGFR) ≤90 mL\u002Fmin\u002F1.73 m\\^2\n* Has a history of clinically significant endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases\n* Has a history of stomach or intestinal surgery or resection that would potentially alter absorption and\u002For excretion of orally administered drugs (uncomplicated appendectomy and hernia repair are allowed)\n* Has a history of cancer (malignancy)\n* Is taking any medication that contains emtricitabine (FTC) or lamivudine (3TC)",true,"ALL","18 Years","55 Years",{"count":79,"type":80},44,"ESTIMATED","INTERVENTIONAL",[83],"PHASE1","Researchers are studying a medicine called MK-8527 to learn how it behaves in the body of healthy adults.\n\nThe goal of this study is to learn about the effect of MK-8527 when it is taken with food or with other medicines. Researchers also want to learn about the safety of MK-8527 and if people tolerate it. Tolerate means participants will receive treatment in the trial unless they need to stop it due to health problems.",[86],"Healthy","2026-06-30",{"date":89,"type":90},"2026-07-02","ACTUAL",{"date":87,"type":90},{"date":93,"type":80},"2026-10-09",{"name":5,"class":6},1]